Portfolio news 0

DeepMatter Group Plc (AIM: DMTR, "DeepMatter", the "Group"), the international digital chemistry data company, has published its unaudited results for the six months to 30 June 2021.

Highlights

• Increasing commercial traction including multi-year licensing deal with Merck's life sciences business
• Data growth and technology integrations with university partners in: discovery and development digital workflow; automated precision manufacturing; and machine learning for sustainable chemistry
• Cemented industry relationships with a number of key managerial appointments
• Secured new customers with strong industry pedigree - active users up 48%
• H1 revenue up to £0.65m (H1 2020: £0.53m)
• R&D higher - reflecting continued investment in products
• Administrative costs down 9% to £1.03m
• H1 loss £1.4m (H1 2020: loss £1.2m).

Mark Warne, DeepMatter CEO , commented:

"We have seen positive momentum in H1 and have enhanced our position in a growing market.  We continued to resource our sales and R&D capabilities to strengthen our offering.

"Our focus is on unlocking the value in digital chemistry by building a fully integrated digital chemistry cloud platform of chemical reaction data for scientists.

"On the back of a strong renewals base and our new focus on growing revenues with those customers as well as growth in users and trials, we look forward with increasing confidence to delivering on our potential and the growth we envisage for 2021 and beyond."

For more information:

DeepMatter Group Plc	0141 548 8156
Mark Warne, Chief Executive Officer
Canaccord Genuity Limited (Nominated Advisor and Broker)	020 7523 8000
Bobbie Hilliam
Meare Consulting	07990 858548
Adrian Duffield

 

About DeepMatter Group Plc 

DeepMatter is building a unique, fully integrated digital chemistry cloud platform of chemical reaction data for scientists, who are working on early-stage chemical discovery & development.

DeepMatter is integrating technology with chemistry to enable scientists, principally in the commercial sector, to easily perform and optimise chemistry.  It is building, structuring and analysing chemical reaction databases and using this substantial data for real-time innovation and productivity gains in the chemical industry - particularly pharmaceutical companies engaged in pre-clinical drug discovery & development.  This data is also now enabling Artificial Intelligence (AI) driven chemical automation.